Alnylam

FDA Extends Action Date on Akcea's Inotersen, Alnylam Now in Lead
CP Wire
Fri, 05/4/18 - 09:58 am
Akcea
hereditary ATTR amyloidosis
FDA
inotersen
Alnylam
Patisiran
FDA Extends Action Date on Akcea's Inotersen, Alnylam Now in Lead
Fri, 05/4/18 - 09:54 am
Akcea Therapeutics
inotersen
Alnylam
Patisiran
Alnylam and FDA Agree on Primary Endpoint for Lumasiran in Primary Hyperoxaluria Type 1 Study
CP Wire
Thu, 05/3/18 - 11:34 am
Alnylam
lumasiran
Primary Hyperoxaluria
Alnylam and FDA Agree on Primary Endpoint for Lumasiran in Primary Hyperoxaluria Type 1 Study
Thu, 05/3/18 - 11:12 am
Alnylam
lumasiran
Primary Hyperoxaluria
EU Advisory Group Backs Orphan Drug Designation for Alnylam's ALN-TTRsc02 for ATTR Amyloidosis
CP Wire
Mon, 04/23/18 - 11:01 am
Alnylam
EMA
orphan drugs
ALN-TTRsc02
ATTR amyloidosis
EU Advisory Group Backs Orphan Drug Designation for Alnylam's ALN-TTRsc02 for ATTR Amyloidosis
Mon, 04/23/18 - 09:37 am
Alnylam
amyloidosis
ALN-TTRsc02
Biotech companies Alnylam, Dicerna settle trade secrets case
Reuters
Sat, 04/21/18 - 12:40 pm
Alnylam
Dicerna
trade secrets
gene silencing
Why Pfizer's Big Win Is Bad News for Alnylam and Ionis
Yahoo/Motley Fool
Mon, 04/2/18 - 03:07 pm
Pfizer
Alnylam
Ionis Pharmaceuticals
tafamidis
inotersen
Patisiran
Pfizer's rare heart disease drug succeeds in late-stage study
Yahoo/Reuters
Fri, 03/30/18 - 09:35 am
Pfizer
clinical trials
tafamidis
transthyretin cardiomyopathy
rare disease
Alnylam
Ionis Pharmaceuticals
3 Blockbuster Drug Launches to Watch In 2018
Motley Fool
Mon, 03/26/18 - 10:45 am
drug launches
Gilead Sciences
HIV
Biktarvy
Alnylam
Sanofi
Patisiran
Epidiolex
GW Pharma
Regeneron, Alnylam partner to turn discovery into new drugs for NASH
Biopharma Dive
Thu, 03/22/18 - 10:26 pm
Regeneron
Alnylam
NASH
R&D
drug discovery
12 blockbusters: The surging list of $1B-plus drugs rolling out on the market this year might surprise you
Endpoints
Thu, 03/22/18 - 09:21 am
drug launches
Hemlibra
Roche
Biktarvy
Gilead Sciences
Ozempic
Novo Nordisk
Erleada
JNJ
Shingrix
GSK
Patisiran
Alnylam
Sanofi
Epidiolex
GW Pharma
Aimovig
Amgen
Novartis
lanadelumab
Shire
Elagolix
AbbVie
Steglatro
Pfizer
Merck
Sublocade
Indivior
Ionis Sends Nerve Drug to Spinout Akcea as Battle with Alnylam Looms
Xconomy
Thu, 03/15/18 - 11:09 am
Ionis Pharmaceuticals
Akcea
Alnylam
transthyretin amyloidosis
inotersen
IONIS-TTR-Lrx
A biopharma CEO's 5 wishes for Trump’s State of the Union address
Stat
Tue, 01/30/18 - 06:14 pm
Donald Trump
John Maraganore
Alnylam
drug pricing
FDA
HHS
healthcare reform
opioid crisis
Three Interviews From the J.P. Morgan Healthcare Conference
Motley Fool
Mon, 01/15/18 - 06:37 pm
JPMHC 2018
Alnylam
Arena Pharmaceuticals
Spark Therapeutics
Will 2018 Be Alnylam Pharmaceuticals, Inc.'s Best Year Yet?
Yahoo/Motley Fool
Mon, 01/15/18 - 09:35 am
Alnylam
givosiran
Patisiran
Alnylam kicks off #JPM18 with a restructured Sanofi deal, grabbing global rights to patisiran
Endpoints
Mon, 01/8/18 - 09:45 am
Alnylam
Sanofi
JPMHC 2018
Patisiran
Alnylam, Sanofi given the all-clear to resume fitusiran trials
BioPharma Dive
Sun, 12/17/17 - 10:24 am
Alnylam
Sanofi
clinical trials
fitusiran
hemophilia
8 Takeout targets to watch in 2018
BioPharma Dive
Sat, 12/16/17 - 08:41 am
M&A
Allergan
Alnylam
Biomarin
Bristol-Myers Squibb
Incyte
Madrigal Pharmaceuticals
Spark Therapeutics
Sucampo
Four months after patient death, FDA’s hold lifted on Alnylam’s fitusiran
Endpoints
Fri, 12/15/17 - 09:32 am
patients
FDA
Alnylam
fitusiran

Pages